Because these processes occur gradually, changes in skin tone tend to be subtle and progressive
Your body may respond more quickly the second time around, since you have prior exposure experience
Most clinical guidelines recommend continuing semaglutide injections during acute COVID-19 infection unless you experience severe nausea, vomiting, or inability to eat
NICE NG28 recommends considering an SGLT2 inhibitor as the preferred option in adults with type 2 diabetes and chronic kidney disease or heart failure, unless contraindicated or not tolerated
Risk factors, gastrointestinal history, pregnancy status, current medications, and any obesity-related conditions help shape the decision
In a two-year clinical trial, 82.2% of participants taking semaglutide reported gastrointestinal symptoms, compared to 53.9% in the placebo group